title: Osteoporosis: which current treatments reduce fracture risk?
abstract: Randomized controlled trials showed that several antiosteoporosis drugs decrease the incidence of fractures, which is a better measure of efficacy than are changes in bone mineral density or serum markers of bone turnover. With effective agents available, physicians should make osteoporosis treatment a priority, especially for patients at high risk, such as those who have already had a fracture.
authors.affiliation: Department of Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, USA.
authors.forename: D T
authors.initials: DT
authors.lastname: Baran
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D002121:Calcium Channel Blockers; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate